anti-CD33
anti-CD33 Brand names, anti-CD33 Analogs
anti-CD33 Brand Names Mixture
- No information avaliable
anti-CD33 Chemical_Formula
No information avaliable
anti-CD33 RX_link
http://www.rxlist.com/cgi/generic2/gemtuzumab.htm
anti-CD33 fda sheet
anti-CD33 msds (material safety sheet)
anti-CD33 Synthesis Reference
(Sequence listed in CO MS, Avdalovic NM, Caron PC, Avdalovic MV, Scheinberg DA, Queen C: Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol 148:1149, 1991) (Caron PC, Schwartz MA, Co MS, Queen C, Finn RD, Graham MC, Divgi CR, Larson SM, Scheinberg DA. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia. Cancer. 1994 Feb 1;73(3 Suppl):1049-56)
anti-CD33 Molecular Weight
No information avaliable
anti-CD33 Melting Point
61 oC (FAB fragment), 71 oC (whole mAb)-Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).
anti-CD33 H2O Solubility
No information avaliable
anti-CD33 State
Liquid
anti-CD33 LogP
No information avaliable
anti-CD33 Dosage Forms
Solution (IV Infusion)
anti-CD33 Indication
For treatment of acute myeloid leukemia
anti-CD33 Pharmacology
Used for the treatment of acute myeloid leukemia (AML), mylotarg binds to the CD33 antigen, which is expressed on the surface of leukemic cells in more than 80% of patients with AML. The CD33 antigen is not expressed on pluripotent hematopoietic stem cells or nonhematopoietic cells. This gives mylotarg the selectivity needed to target leukemic cells.
anti-CD33 Absorption
No information avaliable
anti-CD33 side effects and Toxicity
No information avaliable
anti-CD33 Patient Information
No information avaliable
anti-CD33 Organisms Affected
Humans and other mammals
